Overall, this study contributes to our understanding of the biology of nausea and vomiting in pregnancy and may lead to future research evaluating new treatment avenues. Of note, drugs targeting the GDF15 pathway have shown great promise in mitigating weight loss, loss of appetite, and vomiting in animal models and are currently in clinical trials in cancer cachexia, a disease with similar symptoms to HG.
Read More
In 2023, we will continue our support of families across the globe, continue our groundbreaking research, advocate to change policy to improve maternal and fetal outcomes, and launch an exciting new education program!
Read More
Dr. Marlena Fejzo, geneticist and HER’s Research Advisor and member of the Board of Directors, was featured in the Inverse article, “When morning sickness kills: doctors have dismissed hyperemesis gravidarum for decades, but new research could undo this harmful legacy.”
Read More
HER Board members, Marlena Fejzo, PhD, and Patrick Mullen, MD, are running the first study of GDF15 in HG patients in the United States.
Read More